Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/4/2024 | Buy → Neutral | UBS | ||
8/7/2024 | Neutral → Outperform | Daiwa Securities | ||
7/30/2024 | Equal Weight → Overweight | Barclays | ||
7/10/2024 | $200.00 → $220.00 | Buy | TD Cowen | |
6/28/2024 | $181.00 | Buy → Neutral | Rosenblatt | |
4/16/2024 | Outperform | Evercore ISI | ||
4/8/2024 | $172.00 → $185.00 | Outperform | Oppenheimer | |
3/22/2024 | Buy → Hold | Argus |
4 - Ventas, Inc. (0000740260) (Issuer)
4 - Ventas, Inc. (0000740260) (Issuer)
4 - Ventas, Inc. (0000740260) (Issuer)
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of follow-up, providing sustained bleed protection and potentially avoiding years of treatment burden with prophylaxis for many patients.Pfizer Inc. (NYSE:PFE) today announced that the European Commission (EC) has granted conditional marketing authorization for DURVEQTIX® (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe hemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors and without detectable antibodies to v
Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 21 unusual trades. Delving into the details, we found 42% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $296,355, and 18 were calls, valued at $1,032,173. Expected Price Movements Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $35.0 for Pfizer over the last 3 months. Analyzing Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
SC 13G/A - Ventas, Inc. (0000740260) (Subject)
SC 13G - Ventas, Inc. (0000740260) (Subject)
SC 13G/A - Ventas, Inc. (0000740260) (Subject)
Second-Quarter Performance Driven by Focused Commercial Execution Raises Full-Year 2024 Revenue Guidance(1) to a Range of $59.5 to $62.5 Billion and Raises Adjusted(2) Diluted EPS Guidance to a Range of $2.45 to $2.65 Launched Manufacturing Optimization Program with Anticipated Cost Savings of Approximately $1.5 Billion by the End of 2027 Second-Quarter 2024 Revenues of $13.3 Billion Revenues Grew 3% Operationally Year-over-Year Despite Anticipated Decline in COVID Revenues Excluding Contributions from Comirnaty(3) and Paxlovid, Revenues Grew 14% Operationally Second-Quarter 2024 Reported(4) Diluted EPS of $0.01 and Adjusted(2) Diluted EPS of $0.60 Includes $1.3 Billi
ASML reports €6.2 billion total net sales and €1.6 billion net income in Q2 2024ASML continues to expect 2024 total net sales to be similar to 2023, supported by a strong second half year VELDHOVEN, the Netherlands, July 17, 2024 – Today, ASML Holding NV (ASML) has published its 2024 second-quarter results. Q2 total net sales of €6.2 billion, gross margin of 51.5%, net income of €1.6 billionQuarterly net bookings in Q2 of €5.6 billion2 of which €2.5 billion is EUVASML expects Q3 2024 total net sales between €6.7 billion and €7.3 billion and a gross margin between 50% and 51% (Figures in millions of euros unless otherwise indicated) Q1 2024 Q2 2024
Ventas, Inc. (NYSE:VTR) will issue its second quarter 2024 earnings release after the close of trading on the New York Stock Exchange on Thursday, August 1, 2024. A conference call to discuss those earnings will be held on Friday, August 2, 2024 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). The dial-in number for the conference call is (888) 330-3576 (or +1 (646) 960-0672 for international callers), and the participant passcode is 7655497. A live webcast can be accessed from the Investor Relations section of www.ventasreit.com. A telephonic replay will be available at (800) 770-2030 (or +1 (609) 800-9909 for international callers), passcode 7655497, after the earnings call and wi
SC TO-I/A - PFIZER INC (0000078003) (Subject)
8-K - Ventas, Inc. (0000740260) (Filer)
FWP - Ventas, Inc. (0000740260) (Subject)
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free survival in treatment-naïve patients compared to historical outcomes Results support BRAFTOVI + MEKTOVI as a standard of care option for this population Pfizer Inc. (NYSE:PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow
More than 10 oral and mini-oral presentations span Pfizer's extensive Oncology portfolio of approved and investigational therapies Two late-breaking presentations include longer-term results from BRAFTOVI® + MEKTOVI® PHAROS study in BRAF V600E-mutant metastatic NSCLC and new Phase 2 ponsegromab data in cancer cachexia Encouraging early results for PD-L1 vedotin ADC, disitamab vedotin and the novel combination of CDK4 + CDK2 inhibitors highlight rapidly advancing pipeline Pfizer Inc. (NYSE:PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024,
- Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs across a broad range of cancer types - TOKYO, Sept. 11, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will highlight new data from across its approved and investigational cancer therapies during the 2024 European Society for Medical Oncology (ESMO) Congress being held in Barcelona, Spain on 13-17 September. Eight abstracts across a broad range of cancer types will be presented, reinforcing Astellas' commitment to making a meaningful difference to people living with advanced and hard-to-treat cance
Submission status for PFIZER INC's drug ELREXFIO (SUPPL-2) with active ingredient ELRANATAMAB has changed to 'Approval' on 09/10/2024. Application Category: BLA, Application Number: 761345, Application Classification:
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
UBS downgraded ASML from Buy to Neutral
Daiwa Securities upgraded Pfizer from Neutral to Outperform
Barclays upgraded ASML from Equal Weight to Overweight
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. "As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "His research and development experience will help advance our leading scientific capabilities and
PALO ALTO, Calif., July 18, 2024 /PRNewswire/ -- HiHello, the world's first software platform for digital brand and identity, is thrilled to announce the addition of Shana Simmons and Eugenio Pace to its Board of Directors. Their appointments bring unparalleled expertise and strategic vision to HiHello as the company continues its mission to revolutionize professional networking with an enterprise-ready platform for modern digital business cards. Shana Simmons, who recently joined Zendesk as Chief Legal Officer, brings over 15 years of experience in legal leadership and corporate governance. Prior to Zendesk, Shana served as Chief Legal Officer at Everlaw, a cloud-based e-discovery software
MoneyLion ("MoneyLion") (NYSE:ML), a financial technology ecosystem leader empowering everyone to make their best financial decisions, today announced the appointment of Jon Kaplan as the company's first Chief Revenue Officer ("CRO"). Kaplan brings a wealth of experience and a proven track record of driving growth and innovation at iconic technology companies, including Pinterest (NYSE:PINS) and Google (NASDAQ:GOOG). In this role, Kaplan will lead MoneyLion's go-to-market strategy, with a focus on expanding the market share of MoneyLion's leading digital financial ecosystem. He will also leverage MoneyLion's data assets to deliver new revenue opportunities and drive success for MoneyLion'
4 - PFIZER INC (0000078003) (Issuer)